Effects of ziprasidone, SCH23390 and SB277011 on spatial memory in the Morris water maze test in naive and MK-801 treated mice

• Published in: Pharmacology, biochemistry and behavior Vol. 138; pp. 142 - 147
• Main Authors: Tanyeri, Pelin, Buyukokuroglu, Mehmet Emin, Mutlu, Oguz, Ulak, Güner, Akar, Füruzan Yildiz, Celikyurt, Ipek Komsuoglu, Erden, Bekir Faruk
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.11.2015
• Subjects: Animals; Antipsychotic Agents - pharmacology; Benzazepines - pharmacology; Cognition; Dizocilpine Maleate - pharmacology; Excitatory Amino Acid Antagonists - pharmacology; Male; Maze Learning - drug effects; Mice; Mice, Inbred BALB C; MK-801; Morris water maze; Motor Activity - drug effects; Nitriles - pharmacology; Piperazines - pharmacology; Psychomotor Performance - drug effects; SB277011; SCH23390; Spatial Memory - drug effects; Tetrahydroisoquinolines - pharmacology; Thiazoles - pharmacology; Ziprasidone; MK-801; SB277011; Morris water maze; Ziprasidone; SCH23390; Cognition; Mice
• ISSN: 0091-3057; 1873-5177
• DOI: 10.1016/j.pbb.2015.09.014

Patients with schizophrenia have cognitive dysfunctions; positive psychotic symptoms are the primary purposes for schizophrenia treatment. Improvements in cognitive function should be a characteristic of all newly developed drugs for the treatment of schizophrenia with dementia. Thus, we investigated the effects of the second-generation antipsychotic ziprasidone, dopamine D1 antagonist SCH-23390 and dopamine D3 antagonist SB-277011 on spatial learning and memory. Male inbred mice were used. The effects of ziprasidone, SCH-23390 and SB-277011 were investigated using the Morris water maze test. Ziprasidone (0.5 and 1mg/kg), SCH-23390 (0.05 and 0.1mg/kg) and SB-277011 (10 and 20mg/kg) had no effect on the time spent in the target quadrant in naive mice. MK-801 (0.1mg/kg) significantly decreased the time spent in the target quadrant. The time spent in the target quadrant was significantly prolonged by Ziprasidone (0.5 and 1mg/kg) and SCH-23390 (0.1mg/kg), but not with SB-277011 (20mg/kg) in MK-801-treated mice. Ziprasidone (0.5 and 1mg/kg), SCH-23390 (0.05 and 0.1mg/kg) and SB-277011 (10 and 20mg/kg) had no effect on the mean distance to the platform in naive mice. MK-801 significantly increased the mean distance to the platform. Ziprasidone (1mg/kg) and SCH-23390 (0.1mg/kg) significantly decreased the mean distance to the platform in MK-801-treated mice, but SB-277011 (20mg/kg) didn't. MK-801 significantly increased the total distance moved. Ziprasidone (0.5 and 1mg/kg), SCH-23390 (0.05 and 0.1mg/kg) and SB-277011 (10 and 20mg/kg) had no effect on the total distance moved in naive mice. Ziprasidone (1mg/kg) and SCH-23390 (0.1mg/kg) significantly decreased the total distance moved in MK-801-treated mice, but SB-277011 (20mg/kg) didn't. The second-generation antipsychotic drug ziprasidone and D1 antagonist SCH23390, but not the D3 antagonist SB277011, might be clinically useful for the treatment of cognitive impairments in patients with schizophrenia. •Ziprasidone significantly prolonged the time spent in the target quadrant in MK-801-treated mice.•The time spent in the target quadrant is significantly prolonged by SCH-23390 in MK-801-treated mice.•Ziprasidone significantly decreased the mean distance to the platform in MK-801-treated mice.•SCH-23390 significantly decreased the mean distance to the platform in MK-801-treated mice.